Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

GloriaBio Approved to Launch PD-1 in China for Hodgkin's Lymphoma

publication date: Aug 31, 2021

Gloria Biosciences was approved to launch its anti-PD-1 mAb to treat recurrent or refractory classical Hodgkin’s lymphoma. The PD-1, zimberelimab, was discovered by CRO WuXi Biotech using Ligand Pharma's OmniRat® program. Gloria has rights to zimberelimab in China. GloriaBio is also testing zimberelimab in solid tumors and has been granted Breakthrough status for cervical cancer patients in China. The company, also known as Guangzhou Yuheng Biological, was established in 2016 by Yuheng Pharma and WuXi Biotech. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital